David Charles Lubner - Net Worth and Insider Trading

David Charles Lubner Net Worth

The estimated net worth of David Charles Lubner is at least $52,621 dollars as of 2024-04-29. David Charles Lubner is the Director of POINT Biopharma Global Inc and owns about 3,600 shares of POINT Biopharma Global Inc (PNT) stock worth over $45,000. David Charles Lubner is also the SVP and CFO of Tetraphase Pharmaceuticals Inc and owns about 3,464 shares of Tetraphase Pharmaceuticals Inc (TTPH) stock worth over $7,621. Details can be seen in David Charles Lubner's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that David Charles Lubner has not made any transactions after 2022-11-23 and currently still holds the listed stock(s).

Transaction Summary of David Charles Lubner

To

David Charles Lubner Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, David Charles Lubner owns 9 companies in total, including Dyne Therapeutics Inc (DYN) , Therapeutics Acquisition Corp (RACA) , and Ra Pharmaceuticals Inc (RARX) among others .

Click here to see the complete history of David Charles Lubner’s form 4 insider trades.

Insider Ownership Summary of David Charles Lubner

Ticker Comapny Transaction Date Type of Owner
DYN Dyne Therapeutics Inc 2020-09-16 director
RACA Therapeutics Acquisition Corp 2020-07-07 director
RARX Ra Pharmaceuticals Inc 2020-04-02 Executive VP and CFO
NITE Nightstar Therapeutics PLC 2019-06-07 director
TTPH Tetraphase Pharmaceuticals Inc 2015-08-14 SVP and CFO
ACLX Arcellx Inc 2022-02-03 director
PNT POINT Biopharma Global Inc 2022-11-23 director
IRON Disc Medicine Inc 2021-10-04 director
VOR Vor Biopharma Inc 2021-02-04 director

David Charles Lubner Latest Holdings Summary

David Charles Lubner currently owns a total of 2 stocks. Among these stocks, David Charles Lubner owns 3,600 shares of POINT Biopharma Global Inc (PNT) as of November 23, 2022, with a value of $45,000 and a weighting of 85.52%. David Charles Lubner also owns 3,464 shares of Tetraphase Pharmaceuticals Inc (TTPH) as of August 14, 2015, with a value of $7,621 and a weighting of 14.48%.

Latest Holdings of David Charles Lubner

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PNT POINT Biopharma Global Inc 2022-11-23 3,600 12.50 45,000
TTPH Tetraphase Pharmaceuticals Inc 2015-08-14 3,464 2.20 7,621

Holding Weightings of David Charles Lubner


David Charles Lubner Form 4 Trading Tracker

According to the SEC Form 4 filings, David Charles Lubner has made a total of 1 transactions in POINT Biopharma Global Inc (PNT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in POINT Biopharma Global Inc is the acquisition of 3,600 shares on November 23, 2022, which cost David Charles Lubner around $24,660.

According to the SEC Form 4 filings, David Charles Lubner has made a total of 0 transactions in Tetraphase Pharmaceuticals Inc (TTPH) over the past 5 years. The most-recent trade in Tetraphase Pharmaceuticals Inc is the sale of 475 shares on August 14, 2015, which brought David Charles Lubner around $407,740.

Insider Trading History of David Charles Lubner

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

David Charles Lubner Trading Performance

GuruFocus tracks the stock performance after each of David Charles Lubner's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David Charles Lubner is 8.6%. GuruFocus also compares David Charles Lubner's trading performance to market benchmark return within the same time period. The performance of stocks bought by David Charles Lubner within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how David Charles Lubner's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of David Charles Lubner

Average Return

98.18%

Average return per transaction

Outperforming Transactions

100%

1 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 0.29 8.6 45.63 98.18
Relative Return to S&P 500(%) 4.82 8.97 42.69 85.04

David Charles Lubner Ownership Network

Ownership Network List of David Charles Lubner

No Data

Ownership Network Relation of David Charles Lubner


David Charles Lubner Owned Company Details

What does Dyne Therapeutics Inc do?

Who are the key executives at Dyne Therapeutics Inc?

David Charles Lubner is the director of Dyne Therapeutics Inc. Other key executives at Dyne Therapeutics Inc include Chief Medical Officer Wildon Farwell , See Remarks Richard William Scalzo , and Chief Operating Officer Susanna Gatti High .

Dyne Therapeutics Inc (DYN) Insider Trades Summary

Over the past 18 months, David Charles Lubner made no insider transaction in Dyne Therapeutics Inc (DYN). Other recent insider transactions involving Dyne Therapeutics Inc (DYN) include a net sale of 241,325 shares made by Jonathan Mcneill , a net sale of 191,946 shares made by Richard William Scalzo , and a net sale of 1,171,794 shares made by Joshua T Brumm .

In summary, during the past 3 months, insiders sold 4,521,380 shares of Dyne Therapeutics Inc (DYN) in total and bought 0 shares, with a net sale of 4,521,380 shares. During the past 18 months, 5,472,903 shares of Dyne Therapeutics Inc (DYN) were sold and 3,583,447 shares were bought by its insiders, resulting in a net sale of 1,889,456 shares.

Dyne Therapeutics Inc (DYN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Dyne Therapeutics Inc Insider Transactions

No Available Data

David Charles Lubner Mailing Address

Above is the net worth, insider trading, and ownership report for David Charles Lubner. You might contact David Charles Lubner via mailing address: C/o Tetraphase Pharmaceuticals, Inc., 480 Arsenal Street, Suite 110, Watertown Ma 02472.

Discussions on David Charles Lubner

No discussions yet.